This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Marker Therapeutics (MRKR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.
Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.
Will Marker Therapeutics Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Marker Therapeutics.
MARKER THERAPEUTICS, INC. (MRKR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 7.69% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
These 5 Stocks Make Great Buys on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.